{"id":195707,"date":"2024-04-17T11:24:21","date_gmt":"2024-04-17T21:24:21","guid":{"rendered":"https:\/\/www.hawaii.edu\/news\/?p=195707"},"modified":"2024-04-17T14:11:05","modified_gmt":"2024-04-18T00:11:05","slug":"immunotherapy-breast-cancer-study","status":"publish","type":"post","link":"https:\/\/www.hawaii.edu\/news\/2024\/04\/17\/immunotherapy-breast-cancer-study\/","title":{"rendered":"Immunotherapy shows promise for aggressive breast cancer"},"content":{"rendered":"Reading time: <\/span> < 1<\/span> minute<\/span><\/span>

\"blur<\/p>\n

University of Hawaiʻi<\/span> Cancer Center<\/a> researchers have conducted a phase II<\/abbr> clinical trial to evaluate the safety and effectiveness of pembrolizumab maintenance therapy, a type of immunotherapy in aggressive forms of breast cancer. The study aims to determine if it could offer a less toxic and more targeted alternative to traditional chemotherapy, thus improving patients’ quality of life.<\/p>\n

The trial was led by Naoto T. Ueno, 东精影业<\/abbr> Cancer Center director, and Toshiaki Iwase, assistant professor and medical director, and was conducted at their former institution, The University of Texas MD<\/abbr> Anderson Cancer Center. <\/p>\n

The study produced significant findings that were recently published in Clinical Cancer Research<\/a><\/em>.<\/p>\n

“Undergoing pembrolizumab maintenance therapy made a huge difference in my cancer treatment,” said Deborah Sumulong, a cancer patient who underwent chemotherapy and struggled with allergic reactions, as well as hair loss and lingering fatigue. “I experienced less fatigue; the only side effect was mild colitis (colon inflammation). My scans also showed the cancer declined, with the recent one showing it was completely gone.”<\/p>\n

“While the findings are promising, further research, including a large prospective clinical trial, is necessary to validate the identified biomarkers and refine patient selection criteria for pembrolizumab therapy,” said Iwase.<\/p>\n

Read more on the 东精影业<\/abbr> Cancer Center website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

The study evaluated the safety and effectiveness of pembrolizumab as a maintenance therapy following chemotherapy.<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[218,1363,1600,158,169,9],"class_list":["post-195707","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","tag-cancer","tag-manoa-research","tag-public-impact-research","tag-publication","tag-uh-cancer-center","tag-uh-manoa","entry","has-media"],"aioseo_notices":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts\/195707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/comments?post=195707"}],"version-history":[{"count":5,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts\/195707\/revisions"}],"predecessor-version":[{"id":195817,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts\/195707\/revisions\/195817"}],"wp:attachment":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/media?parent=195707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/categories?post=195707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/tags?post=195707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}